Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells

M Sykes, M L Romick, D H Sachs, M Sykes, M L Romick, D H Sachs

Abstract

We have recently demonstrated that interleukin 2 (IL-2), when administered in high doses for several days beginning on the day of allogeneic bone marrow transplantation (BMT), markedly diminishes graft-versus-host disease (GVHD) mortality in lethally irradiated mice. An optimal anti-GVHD effect was attained by coadministering T-cell-depleted (TCD) syngeneic marrow. We demonstrate here that the full graft-versus-leukemia effect of allogeneic T lymphocytes is obtained even when GVHD is markedly diminished by the coadministration of IL-2 and TCD syngeneic marrow. This methodology represents an approach to the treatment of leukemia in which the beneficial effects of allogeneic T cells can be exploited while their major deleterious effect, GVHD, is avoided. These results may thus have an impact on the clinical use of BMT for the treatment of hematologic malignancies.

References

    1. Immunogenetics. 1981;12(1-2):183-6
    1. Br J Cancer. 1950 Dec;4(4):372-9
    1. Transplantation. 1982 Sep;34(3):113-20
    1. J Biol Response Mod. 1984 Oct;3(5):561-72
    1. J Exp Med. 1985 May 1;161(5):1169-88
    1. J Exp Med. 1985 Jul 1;162(1):231-44
    1. J Immunol. 1986 Jan;136(1):28-33
    1. J Immunol. 1987 Jun 1;138(11):3640-5
    1. Transplantation. 1987 Jun;43(6):842-7
    1. Annu Rev Immunol. 1987;5:43-64
    1. Cancer Res. 1988 Apr 1;48(7):1965-71
    1. J Immunol. 1988 Jun 1;140(11):4062-9
    1. J Immunol. 1988 Oct 1;141(7):2282-8
    1. Nat Immun Cell Growth Regul. 1988;7(3):180-4
    1. Lab Invest. 1988 Nov;59(5):598-612
    1. Bone Marrow Transplant. 1988 Sep;3(5):445-56
    1. Nouv Rev Fr Hematol. 1988;30(5-6):475-8
    1. Blood. 1989 Apr;73(5):1340-50
    1. Transplant Proc. 1989 Feb;21(1 Pt 3):3022-4
    1. Blood. 1989 May 1;73(6):1720-8
    1. Bone Marrow Transplant. 1989 Sep;4(5):465-74
    1. Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5
    1. J Immunol. 1989 Dec 1;143(11):3503-11
    1. J Exp Med. 1990 Mar 1;171(3):645-58
    1. N Engl J Med. 1981 Jun 18;304(25):1529-33

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj